Supplementary Material

Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent

Jin Cheng^a John Fuller^a Regina Feldman^a William Tap^b Takashi Owa^c Zvi Fuks^d Richard Kolesnick^a

^aLaboratory of Signal Transduction, Memorial Sloan Kettering Cancer Center, New York, NY, USA, ^bSarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA, ^cOncology Business Group, Eisai Co Ltd, Koishikawa, Bunkyo-Ku, Tokyo, Japan, ^dDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Table S1:

	50mg/kg (4 mice)	100mg/kg (2 mice)	150mg/kg (3 mice)	200mg/kg (3 mice)
0-2 hours	Good Condition	Good Condition	Good Condition	Slight Lethargy
2-24 hours	Good Condition	Good Condition	Good Condition	Good Condition
24-48 hours	Good Condition	Good Condition	Good Condition	Good Condition
48-72 hours	Good Condition	Good Condition	Good Condition	Good Condition

Table S1. Acute lenvatinib toxicity trial. Lenvatinib was resuspended at 5mg/ml in sterile water in a light protected vial and mixed for 4 hours at 4°C. Lenvatinib was delivered to sv129/BL6 mice via oral gavage at four doses: 50, 100, 150, 200 mg/kg. Three mice were used for each dose. Mice were observed closely for tremors, convulsions, salivation, diarrhea, lethargy, sleepiness and coma during the first two hours, and thereafter every 8 hours until 72 hours, followed by daily for 7 days. No reaction was observed in any of the mice beyond slight lethargy in the highest dose group within the first 5 to 10 min after initial gavage. Control mice receiving a comparable volume of sterile water alone displayed a similar reaction (not shown). Lenvatinib-treated mice were housed for 60 days. Lenvatinib-treated mice were housed for 60 days. All treated mice were viable at that time with no signs or symptoms of stress or toxicity.